A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.
A well-established family of drugs used to treat parasitic diseases is showing surprising potential as a therapy for tuberculosis (TB), according to new research from University of British Columbia microbiologists.
Researchers with the Neglected Global Diseases Initiative (NGDI) at the University of British Columbia have attracted more than $20 million in funding to find ways to eliminate diseases and conditions that kill millions of people in developing countries worldwide.
A drug delivery system developed through the University of British Columbia’s Neglected Global Diseases Initiative and licensed to iCo Therapeutics Inc. will receive $1.1 million from the National Research Council of Canada (NRC) for clinical development as a treatment for HIV patients.
Researchers from the University of British Columbia, Child & Family Research Institute (CFRI) and BC Children’s Hospital (BCCH) have won a $2.8-million grant from the Canadian International Development Agency (CIDA) to improve the survival rate of Bangladeshi mothers, newborns and young children through the prevention of sepsis, a life-threatening form of infection in which the bloodstream is overwhelmed by bacteria.
Three research projects at the University of British Columbia have won five-year grants totaling nearly $6 million from the Canadian Institutes of Health Research (CIHR) to promote greater equity in global health.
The University of British Columbia has received a $7 million grant from the Bill & Melinda Gates Foundation. UBC researchers working at the Child & Family Research Institute will test new strategies for the monitoring, prevention, and treatment of pre-eclampsia.